{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:39:01Z","timestamp":1760981941895},"reference-count":11,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T00:00:00Z","timestamp":1153094400000},"content-version":"vor","delay-in-days":4925,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1993,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A total of 351 patients with thoracic esophageal carcinoma were prospectively classified according to the new (1987) TNM classification. Sixty\u2010two patients received chemotherapy and\/or radiotherapy without surgery. Esophagectomy was performed on 291 patients, among whom 139 underwent cervical, mediastinal and abdominal lymph adenectomy (3\u2010field dissection). The number of stage IIB patients was unnaturally small, and the 3\u2010year survival rates of stages IIA and IIB were similar. The survival curves for patients of T, N and M categories distributed well except for those of stages IIA and IIB. Numbers of patients in N and <jats:sub>p<\/jats:sub>N categories and those in M and <jats:sub>p<\/jats:sub>M categories showed poor coincidence. The 5\u2010year survival rate for MI patients (IO.Wo) was too good, which suggested the mingling of patients with rather better prognosis. When MI (LYM) patients were excluded from M I, the 3\u2010year survival rate fell to 0.3%. The 5\u2010year survival rate for <jats:sub>p<\/jats:sub>M I (LYM) patients who underwent 3\u2010field dissection was 38.2%. Survival rates and numbers of positive nodes showed negative correlation in patients who underwent 3\u2010field dissection. According to these results, we propose the following revision in the next TNM classification: (I) to group stage IIA and stage IIB together to form Stage II; (2) to include cervical and coeliac lymph nodes among the regional lymph nodes, or to designate metastasis in non\u2010regional lymph nodes separately from metastasis in viscera; and (3) to divide N I into N1 and N2 according to the number of positive lymph nodes.<\/jats:p>","DOI":"10.1002\/ijc.2910530208","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T23:27:34Z","timestamp":1171927654000},"page":"220-223","source":"Crossref","is-referenced-by-count":42,"title":["Evaluation of the new (1987) TNM classification for thoracic esophageal tumors"],"prefix":"10.1002","volume":"53","author":[{"given":"Hoichi","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tachimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(58)90126-7"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/52.1-2.203"},{"key":"e_1_2_1_4_1","first-page":"57","volume-title":"TNM classification of malignant tumors","author":"Harmer M. H.","year":"1978"},{"key":"e_1_2_1_5_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/978-3-642-82982-6","volume-title":"TNM classification of malignant tumours. Fourth, fully revised edition.","author":"Hermanek P.","year":"1987"},{"key":"e_1_2_1_6_1","first-page":"625","article-title":"A proposal for a new TNM classification of esophageal carcinoma","volume":"14","author":"Japanese Committee FOR Registration OF Esophageal Carcinoma","year":"1985","journal-title":"Jap. J. clin. Oncol."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000226971"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901201)66:11<2319::AID-CNCR2820661111>3.0.CO;2-1"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(91)91008-J"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198610000-00007"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910530208","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910530208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T05:20:15Z","timestamp":1695878415000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910530208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,1,21]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1993,1,21]]}},"alternative-id":["10.1002\/ijc.2910530208"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910530208","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,1,21]]}}}